Drug Index


Mechanism :

Ganciclovir is an acyclic nucleoside analogue of 2-deoxyguanosine that inhibits replication of herpes viruses. Ganciclovir has been shown to be active against cytomegalovirus (CMV) and herpes simplex virus (HSV) in human clinical studies.

Indication :

  • Prevention of cytomegalovirus (CMV) disease in advanced HIV infection at risk for CMV disease
  • Prevention of CMV disease in solid organ transplant recipients
  • Treatment of CMV retinitis in immunocompromised patients
  • Treatment of Congenital CMV

Contraindications :

Contraindicated in patients with hypersensitivity to ganciclovir or acyclovir. Ensure adequate hydration when using IV. Avoid in patients with neutrophil count <500 cell per microlitre. Regular-monitoring of white blood cell count is advised.

Dosing :

Congenital CMV:
6 mg/kg/dose twice a day intravenously every day for 6 weeks.
CMV disease and prophylaxis:
10 mg/kg/24 hours IV divided into 2 doses given 12 hourly for 7-14 days followed by maintenance of 5-6 mg/kg/24 hours IV once daily.
Oral dose:For maintenance
30-90 mg/kg/day in 2 divided doses; Max 1000 mg/day.

Adverse Effect :

Neutropenia, thrombocytopenia, anemia, rash, abnormal LFTs, chills, edema, confusion ataxia, nervousness, paresthesia, psychosis, tremor, hypotension, hypertension, cardiac arrhythmias, gastrointestinal hemorrhage, eosinophilia, decreased blood glucose, alopecia, pruritus, urticaria, hematuria, increase in serum creatinine and urea.

Interaction :

Zidovudine: Since both zidovudine and ganciclovir have the potential to cause neutropenia and anemia, some patients may not tolerate concomitant therapy with these drugs at full dosage.
Probenecid: Renal clearance of ganciclovir decreased which is consistent with an interaction involving competition for renal tubular secretion.
Imipenem-cilastatin: Generalized seizures have been reported in patients who received ganciclovir and imipenem-cilastatin. These drugs should not be used concomitantly unless the potential benefits outweigh the risks.
Dapsone, Pentamidine, Flucytosine, Vincristine, Vinblastine, Adriamycin, Amphotericin B, Trimethoprim/Sulfamethoxazole Combinations or other Nucleoside Analogues: Drugs that inhibit replication of rapidly dividing cell populations such as bone marrow, spermatogonia and germinal layers of skin and gastrointestinal mucosa may have additive toxicity when administered concomitantly with ganciclovir. Therefore, such drugs, should be considered for concomitant use with ganciclovir only if the potential benefits are judged to outweigh the risks involved.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)

Dose in Patients undergoing Renal Replacement Therapies
CAPDDialysed. 1.25 mg/kg every day
HDDialysed. 1.25 mg/kg every day, given post dialysis on dialysis days
HDF/High fluxDialysed. 1.25 mg/kg every day, given post dialysis on dialysis days
CAV/VVHDDialysed. 2.5 mg/kg per day

Hepatic Dose :

No dosage adjustments are needed.
01/18/2024 18:16:34 Ganciclovir
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0